A Phase 3 interventional study of DTG and LPV/RTV in HIV Infections, sponsored by ViiV Healthcare. Completed at 59 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-13.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.
Among the 55 studies testing dolutegravir in HIV Infections, this one is the 9th largest by enrollment, is one of 4 that started in 2014, is one of 21 in phase 3, and was the 16th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in Romania, South Africa, Uganda
José Antonio Mata Marín · Sites in Mexico
Ages 18–70
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+
José Antonio Mata Marín · Sites in Mexico
Ages 18–70 · Men only
ViiV Healthcare · Sites in United States
Ages 6–12
By country, each count listing its studies:
Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 15 · Phase 3 24 · Phase 4 11
First in 2009; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 627 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 126 across the 55 interventional studies. Of the 43 that completed or were terminated, 26 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 16th largest by enrollment of the 210 interventional ones that give a count, is one of 5 that started in 2014, is one of 65 in phase 3, and was the 156th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing dolutegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07031063Instituto Mexicano del Seguro SocialSafety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 55 studies testing dolutegravir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
For treatment of human immunodeficiency virus type 1(HIV-1), publicly funded programmes tend to follow World Health Organization (WHO) guidelines to use a non-nucleoside reverse transcriptase inhibitor (NNRTI) combined with two nucleoside reverse transcriptase inhibitors (NRTIs) for first-line antiretroviral therapy (ART); however, there is a need for further data on the best treatment options for people with HIV-1 who have virological failure with this first-line regimen. The number of patients failing on their first-line regimen is increasing thereby requiring a switch to second-line treatment to reduce accumulation of drug-resistance mutations, disease progression, HIV transmission, and death. WHO guidelines recommend second-line antiretroviral therapy for adults consisting of two NRTIs + a ritonavir-boosted protease inhibitor (PI); atazanavir (ATV) plus ritonavir (RTV) or lopinavir (LPV)/RTV are the preferred boosted PI options. This study is conducted to demonstrate non-inferior antiviral activity at 48 weeks of a dolutegravir (DTG) containing regimen compared to a WHO-recommended standard of care regimen for second line treatment, LPV/RTV + two NRTIs, in HIV-1 infected patients failing first line therapy. This study comprises of a Screening Phase (approximately 28 to 42 days), a Randomized Phase (Day 1 to Week 48 plus a 4-week treatment extension), and a Continuation Phase. Approximately 612 subjects will be randomized 1:1 to receive DTG 50 milligram (mg) once daily or LPV/RTV (800/200 mg once daily or 400/100 mg twice daily, in accordance with investigator decision and local label), each added to an investigator selected background regimen of two NRTIs at least one of which needs to be fully active based on viral resistance testing at Screening. Subjects randomized to the LPV/RTV arm will either (i) continue receiving LPV/RTV and complete the study after the 4-week treatment extension at Week 52, or (ii) switch to the DTG arm prior to study completion at Week 52 and continue to have access to DTG in the Continuation Phase. Subjects randomized to receive DTG who successfully complete 52 weeks of treatment and subjects originally randomized to receive LPV/RTV but switched to DTG prior to Week 52 will continue to have access to DTG until it is either locally approved and commercial supplies are available to patients or the patient no longer derives clinical benefit, or the patient meets a protocol-defined reason for discontinuation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
is of non- defined as either (12 months of spontaneous amenorrhea and >=45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy, or bilateral oophorectomy or, is of child-bearing potential, with a negative pregnancy test at both Screening and Day 1 and agrees to use one of the protocol-defined methods of to avoid pregnancy throughout the study and for at least 2 weeks after discontinuation of all study medication.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive one oral tablet of 50 mg DTG once daily plus two NRTIs selected by the investigator
Drug: DTG · Drug: Two NRTIs
Subjects will receive four oral tablets of200/50 mg LPV/RTV once daily or two oral tablets of 200/50 mg LPV/RTV twice daily plus two NRTIs selected by the investigator
Drug: LPV/RTV · Drug: Two NRTIs
DTG is supplied as 50 mg tablets
LPV/RTV is supplied as the LPV/RTV oral tablet, which contains 200 mg of LPV and 50 mg of RTV
Investigators will choose a dual NRTI background regimen for each subject . In consultation with the medical monitor, 3TC may be added as a third NRTI to a dual-NRTI background regimen in subjects with chronic HBV infection and evidence of HIV resistance to 3TC
Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies Per Milliliter (c/mL) at Week 48
Percentage of participants with plasma HIV 1 RNA \<50 c/mL at Week 48 using the Food and Drug Administration (FDA) snapshot algorithm was assessed to demonstrate the non-inferior activity of DTG plus 2 NRTI's compared to LPV/RTV plus 2 NRTI's. Analysis was performed on Intent-to-treat exposed (ITT-E) Population, which comprised of all randomized participants who received at least one dose of study medication. Percentage values are rounded off.
Time frame: Week 48
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24
Percentage of participants with plasma HIV 1 RNA \<50 c/mL at Week 24 using the FDA snapshot algorithm was assessed to demonstrate the non-inferior activity of DTG plus 2 NRTI's compared to LPV/RTV plus 2 NRTI's. Percentage values are rounded off.
Time frame: Week 24
Percentage of Participants With Plasma HIV-1 RNA <400 c/mL at Weeks 24 and 48
Percentage of participants with plasma HIV 1 RNA \<400 c/mL at Week 24 and 48 using the FDA snapshot algorithm were evaluated. Percentage values are rounded off.
Time frame: Week 24 and Week 48
Percentage of Participants Without Virologic or Tolerability Failure at Week 24 and Week 48
Virologic or tolerability failure was defined as treatment-related discontinuation (meeting confirmed virologic withdrawal criteria, treatment-related adverse event, safety stopping criteria, and lack of efficacy). Percentage of participants without virologic failure by Week 24 and Week 48 have been presented. Participants who did not met the protocol defined confirmed virologic withdrawal criteria and are ongoing in the study, or who had discontinued for non-treatment related reasons were censored.
Time frame: Week 24 and Week 48
Time to Viral Suppression at Week 48
Viral suppression was defined as HIV-1 RNA \<50 c/mL. Time to viral suppression was analyzed and median and interquartile range has been presented.
Time frame: Week 48
Change From Baseline in Helper-inducer T-lymphocyte Having Surface Antigen Cluster of Differentiation (CD4+) Cell Count at Weeks 24 and 48
Blood was collected and CD4+ cell count assessment was carried out at indicated time points to evaluate the immunological activity of DTG compared to LPV/RTV. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Week 24 and Week 48
Number of Participants With Disease Progression-Randomized + Continuation Phase
Disease progression included HIV-associated conditions, acquired immune deficiency syndrome (AIDS) and death. Number of participants with disease progression to Centers for Disease Control and Prevention (CDC) class C or death have been presented.
Time frame: Up to Week 348
Number of Participants With Treatment-emergent Genotypic Resistance-Randomized Phase
Number of participants, who met confirmed virologic withdrawal (CVW) criteria with paired Baseline and time of CVW resistance data with treatment emergent genotypic resistance to Integrase strand transfer inhibitor (INSTI), NRTI, Protease inhibitor (PI) were summarized. Viral Genotypic Population comprised of all participants in the ITT-E population with available On-treatment genotypic resistance data at the time confirmed virologic withdrawal criterion was met during Randomized Phase.
Time frame: Up to Week 52
Number of Participants With Treatment-emergent Genotypic Resistance-Continuation Phase
Number of participants, who met confirmed virologic withdrawal criteria with paired Baseline and time of CVW resistance data, with treatment emergent genotypic resistance to Integrase strand transfer inhibitor (INSTI), NRTI, Protease inhibitor (PI) were summarized. Analysis was performed on Viral Genotypic Continuation Population which comprised all participants in the ITT-E- Continuation Population with available on-treatment genotypic resistance data in the Continuation Phase.
Time frame: Up to Week 295
Number of Participants With Fold Change in Treatment-emergent Phenotypic Resistance From Baseline-Randomized Phase
Number of participants with fold change in treatment-emergent phenotypic resistance from Baseline to DTG, LPV/RTV was counted to assess the development of viral resistance. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-dose visit value minus Baseline value. Change in grade 0 to \>2 from Baseline is presented. Analysis was performed on viral phenotypic Population, which comprised of all participants in the ITT-E Population with available On-treatment phenotypic resistance data at the time confirmed virologic withdrawal criterion is met during Randomized Phase.
Time frame: Baseline (Day 1, Pre-dose) and up to Week 52
Number of Participants With Fold Change in Treatment-emergent Phenotypic Resistance From Baseline-Continuation Phase
Number of participants with fold change in treatment-emergent phenotypic resistance from Baseline to DTG was counted to assess the development of viral resistance. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-dose visit value minus Baseline value. Change in grade 0 to \>2 from Baseline is presented. Analysis was performed on Viral Phenotypic Continuation Population which comprises all participants in the ITT-E- Continuation Population with available on-treatment phenotypic resistance data in the Continuation Phase.
Time frame: Baseline (Day 1, Pre-dose) and up to Week 295
Number of Participants With Non-serious Adverse Events (AEs) With >=2% Frequency Threshold and Serious Adverse Events (SAEs)-Randomized Phase
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, other situations as per medical or scientific judgment and is associated with liver injury or impaired liver function. Safety Population was used which comprised of all participants who received at least one dose of study treatment. Adverse events which were not Serious were considered as Non-Serious adverse events.
Time frame: Up to Week 52
Number of Participants With Non-serious AEs With >=2% Frequency Threshold and SAEs-Continuation Phase
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, other situations as per medical or scientific judgment and is associated with liver injury or impaired liver function. Adverse events which were not Serious were considered as non-serious AEs.
Time frame: Up to Week 295
Number of Participants With Non-serious AEs With >=2% Frequency Threshold and SAEs-Randomized + Continuation Phase
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, other situations as per medical or scientific judgment and is associated with liver injury or impaired liver function. Adverse events which were not Serious were considered as non-serious AEs.
Time frame: Up to Week 348
Change From Baseline in Glucose, Chloride, Carbon-di-oxide (CO2), Potassium, Phosphate, Sodium, Urea, Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol and Triglycerides
Blood samples were collected from participants to evaluate clinical chemistry parameters including glucose, chloride, carbon-di-oxide (CO2), potassium, phosphate, sodium, urea, cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides. Lipid parameters were evaluated in fasting condition. Change from Baseline in clinical chemistry parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52
Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatine Kinase Values
Blood samples were collected from participants to evaluate clinical chemistry parameters including ALP, ALT, AST and creatine kinase. Change from Baseline in clinical chemistry parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52
Change From Baseline in Albumin Values
Blood samples were collected from participants to evaluate clinical chemistry parameter including albumin. Change from Baseline in clinical chemistry parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52
Change From Baseline in Creatinine and Bilirubin Values
Blood samples were collected from participants to evaluate clinical chemistry parameters including creatinine and bilirubin. Change from Baseline in clinical chemistry parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52
Change From Baseline in Lipase Values
Blood samples were collected from participants to evaluate clinical chemistry parameter including lipase. Change from Baseline in lipase at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52
Number of Participants With Clinical Chemistry Toxicities -Randomized Phase
Number of participants with clinical chemistry toxicities has been presented. Toxicities were based on the Division of AIDS (DAIDS) grading system. Grade 1=Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Potentially life-threatening. Higher the grade, more severe the symptoms. Lipids and glucose parameters were summarized on fasting data. Data has been reported for clinical chemistry parameters including serum glucose, ALT, Albumin, ALP, AST, Bilirubin, CO2, Creatine kinase, LDL cholesterol calculation, LDL cholesterol direct, Lipase, Phosphate, Potassium, Sodium, Cholesterol, Creatinine and Serum Triglycerides.
Time frame: Up to Week 52
Number of Participants With Clinical Chemistry Toxicities-Continuation Phase
Number of participants with clinical chemistry toxicities has been presented. Toxicities were based on the Division of AIDS (DAIDS) grading system. Grade 1=Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Potentially life-threatening. Higher the grade, more severe the symptoms. Lipids and glucose parameters were summarized on fasting data. Data has been reported for clinical chemistry parameters including serum glucose, ALT, Albumin, ALP, AST, Bilirubin, CO2, Creatine kinase, LDL cholesterol calculation, LDL cholesterol direct, Lipase, Phosphate, Potassium, Sodium, Cholesterol, Creatinine and Serum Triglycerides.
Time frame: Up to Week 295
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes
Blood samples were collected from participants to evaluate clinical hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Change from Baseline in clinical hematology parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52
Change From Baseline in Hematocrit Values
Blood samples were collected from participants to evaluate clinical hematology parameter including hematocrit. Change from Baseline in hematocrit values at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and and Week 52
Change From Baseline in Hemoglobin Values
Blood samples were collected from participants to evaluate clinical hematology parameter including hemoglobin. Change from Baseline in hemoglobin values at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and Week 52
Change From Baseline in Mean Corpuscular Volume (MCV)
Blood samples were collected from participants to evaluate clinical hematology parameter including MCV. Change from Baseline in MCV values at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and and Week 52
Change From Baseline in Erythrocyte Values
Blood samples were collected from participants to evaluate clinical hematology parameter including erythrocyte. Change from Baseline in erythrocyte values at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 8, Week 16, Week 24, Week 36, Week 48 and up to Week 52
Number of Participants With Hematology Toxicities -Randomized Phase
Number of participants with hematology toxicities has been presented. Toxicities were based on the Division of AIDS (DAIDS) grading system. Grade 1=Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Potentially life-threatening. Higher the grade, more severe the symptoms. Data has been reported for hematology parameters including Hemoglobin, Leukocytes, Neutrophils and Platelets.
Time frame: Up to Week 52
Number of Participants With Hematology Toxicities-Continuation Phase
Number of participants with hematology toxicities has been presented. Toxicities were based on the Division of AIDS (DAIDS) grading system. Grade 1=Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Potentially life-threatening. Higher the grade, more severe the symptoms. Data has been reported for hematology parameters including Hemoglobin, Leukocytes, Neutrophils and Platelets.
Time frame: Up to Week 295
Number of Participants Who Discontinued Treatment Due to AEs-Randomized Phase
Number of participants who discontinued study treatment due to AEs or SAEs were summarized.
Time frame: Up to Week 52
Number of Participants Who Discontinued Treatment Due to AEs-Continuation Phase
Number of participants who discontinued study treatment due to AEs were summarized.
Time frame: Up to Week 295
Change From Baseline in Fasting LDL Cholesterol at Week 24 and Week 48
Blood samples were collected from participants in fasting state to evaluate LDL cholesterol. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Analysis was performed using multiple imputation with missing at random assumption. Only participants available at the time of evaluation were analyzed.
Time frame: Baseline (Day 1, Pre-dose), Week 24 and Week 48
Change From Baseline in Fasting Total Cholesterol/HDL Cholesterol Ratio
Blood samples were collected from participants in fasting state to evaluate total cholesterol/HDL cholesterol ratio. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Only participants available at the time of evaluation were analyzed. Analysis was performed using multiple imputation with missing at random assumption.
Time frame: Baseline (Day 1, Pre-dose), Week 24 and Week 48
Number of Participants With Maximum Post-Baseline Emergent Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol
Blood samples were collected from participants in fasting state at indicated time-points to evaluate LDL cholesterol. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Number of participants who experienced maximum grade 2 or greater toxicity post-Baseline in fasting LDL cholesterol was summarized. Participants were graded using the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening. Higher the grade, more severe the symptoms.
Time frame: Up to Week 48
Number of Participants With Maximum Post-Baseline Emergent Grade 2 or Greater Drug-related Diarrhea
Number of participants who experienced maximum grade 2 or greater toxicity post-Baseline in drug-related diarrhea was summarized. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Participants were graded using the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening. Higher the grade, more severe the symptoms.
Time frame: Week 24 and Week 48
Change From Baseline in Gastrointestinal Symptom Rating Scale (GSRS) Score
The GSRS is a disease-specific instrument of 15 items combined into five symptom clusters depicting Reflux, Abdominal pain, Indigestion, Diarrhea and Constipation. The scale ranges from 1= no discomfort to 7= very severe discomfort for each symptom cluster. Higher scores show greater severity of symptoms. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. The analysis was performed using Last Observation Carried Forward (LOCF) dataset. In the LOCF dataset, missing values were carried forward from the previous, non-missing available on-treatment assessment.
Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 24, Week 48
Change From Baseline in Treatment Satisfaction, Using the HIV-Treatment Satisfaction Questionnaire (HIVTSQ) Score
The HIVTSQ is a self-reported scales that measure overall satisfaction with treatment. The score ranges from 0-10. The higher the score, the greater the improvement in treatment satisfaction as compared to the past few weeks. A smaller score represents a decline in treatment satisfaction compared to the past few weeks. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. The analysis was performed using LOCF dataset. In the LOCF dataset, missing values were carried forward from the previous, non-missing available on-treatment assessment.
Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 24, Week 48
Number of Participants Showing Adherence With Treatment, Using the Morisky 8-Item Medication Adherence Scale (MMAS-8)
Treatment compliance was evaluated through MMAS-8. It is an eight-item self-reported measure of medication-taking behavior. The score ranges from 0-8 where scores of 8 indicate high or near perfect adherence, and scores of less than 6 indicate poor or inadequate adherence on the MMAS-8 scale. Number of participants showing low, medium and high adherence to treatment are presented. Low adherence is a score 0-5.75, medium adherence is a score of 6-7.75 and high adherence is a score of 8. The analysis was performed using LOCF dataset. In the LOCF dataset, missing values were carried forward from the previous, non-missing available on-treatment assessment.
Time frame: Baseline (Day 1, Pre-dose), Week 4, Week 24 and Week 48
This study assessed antiviral activity and safety of dolutegravir (DTG) in human immunodeficiency virus-1 (HIV-1) infected participants with treatment failure on first line therapy. The study consisted of Randomized Phase followed by Continuation Phase.
| Milestone | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase | Participants Receiving DTG-Continuation Phase |
|---|---|---|---|
| Started | 312 | 315 | 0 |
| Itt-e population | 312 | 312 | 0 |
| Completed | 275 | 245 | 0 |
| Not completed | 37 | 70 | 0 |
| Withdrew: Reached stopping criteria | 0 | 1 | 0 |
| Withdrew: Adverse event | 8 | 18 | 0 |
| Withdrew: Lack of efficacy | 10 | 22 | 0 |
| Withdrew: Protocol violation | 7 | 8 | 0 |
| Withdrew: Withdrawal by subject | 5 | 4 | 0 |
| Withdrew: Physician decision | 0 | 9 | 0 |
| Withdrew: Lost to follow-up | 7 | 5 | 0 |
| Withdrew: Randomized, but did not receive treatment | 0 | 3 | 0 |
| Milestone | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase | Participants Receiving DTG-Continuation Phase |
|---|---|---|---|
| Started | 0 | 0 | 274 |
| Completed | 0 | 0 | 225 |
| Not completed | 0 | 0 | 49 |
| Withdrew: Adverse event | 0 | 0 | 8 |
| Withdrew: Lack of efficacy | 0 | 0 | 16 |
| Withdrew: Protocol violation | 0 | 0 | 8 |
| Withdrew: Withdrawal by subject | 0 | 0 | 6 |
| Withdrew: Physician decision | 0 | 0 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 7 |
Percentage of participants with plasma HIV 1 RNA \<50 c/mL at Week 48 using the Food and Drug Administration (FDA) snapshot algorithm was assessed to demonstrate the non-inferior activity of DTG plus 2 NRTI's compared to LPV/RTV plus 2 NRTI's. Analysis was performed on Intent-to-treat exposed (ITT-E) Population, which comprised of all randomized participants who received at least one dose of study medication. Percentage values are rounded off.
| Percentage of participants | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies Per Milliliter (c/mL) at Week 48 | 84 | 70 |
Percentage of participants with plasma HIV 1 RNA \<50 c/mL at Week 24 using the FDA snapshot algorithm was assessed to demonstrate the non-inferior activity of DTG plus 2 NRTI's compared to LPV/RTV plus 2 NRTI's. Percentage values are rounded off.
| Percentage of participants | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24 | 82 | 69 |
Percentage of participants with plasma HIV 1 RNA \<400 c/mL at Week 24 and 48 using the FDA snapshot algorithm were evaluated. Percentage values are rounded off.
| Percentage of participants | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Week 24 | 90 | 84 |
| Week 48 | 88 | 77 |
Virologic or tolerability failure was defined as treatment-related discontinuation (meeting confirmed virologic withdrawal criteria, treatment-related adverse event, safety stopping criteria, and lack of efficacy). Percentage of participants without virologic failure by Week 24 and Week 48 have been presented. Participants who did not met the protocol defined confirmed virologic withdrawal criteria and are ongoing in the study, or who had discontinued for non-treatment related reasons were censored.
| Percentage of participants | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Week 24 | 97.6 | 91.9 |
| Week 48 | 96.0 | 86.1 |
Viral suppression was defined as HIV-1 RNA \<50 c/mL. Time to viral suppression was analyzed and median and interquartile range has been presented.
| Days | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Time to Viral Suppression at Week 48 | 29.0 (29.0 to 57.0) | 111.0 (35.0 to 167.0) |
Blood was collected and CD4+ cell count assessment was carried out at indicated time points to evaluate the immunological activity of DTG compared to LPV/RTV. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-dose visit value minus Baseline value.
| Cells per cubic millimeter (Cells/mm^3) | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Week 24; n= 291, 285 | 84.0 (31.0 to 146.0) | 82.0 (31.0 to 146.0) |
| Week 48; n= 275, 251 | 120.0 (63.0 to 204.0) | 118.0 (66.0 to 191.0) |
Disease progression included HIV-associated conditions, acquired immune deficiency syndrome (AIDS) and death. Number of participants with disease progression to Centers for Disease Control and Prevention (CDC) class C or death have been presented.
| Participants | DTG in Randomized Phase Followed by Continuation Phase | LPV/RTV-Randomized Phase Followed by DTG in Continuation Phase |
|---|---|---|
| Number of Participants With Disease Progression-Randomized + Continuation Phase | 10 | 7 |
Number of participants, who met confirmed virologic withdrawal (CVW) criteria with paired Baseline and time of CVW resistance data with treatment emergent genotypic resistance to Integrase strand transfer inhibitor (INSTI), NRTI, Protease inhibitor (PI) were summarized. Viral Genotypic Population comprised of all participants in the ITT-E population with available On-treatment genotypic resistance data at the time confirmed virologic withdrawal criterion was met during Randomized Phase.
| Participants | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| INSTI | 3 | 0 |
| NRTI | 1 | 3 |
| PI | 0 | 0 |
Number of participants, who met confirmed virologic withdrawal criteria with paired Baseline and time of CVW resistance data, with treatment emergent genotypic resistance to Integrase strand transfer inhibitor (INSTI), NRTI, Protease inhibitor (PI) were summarized. Analysis was performed on Viral Genotypic Continuation Population which comprised all participants in the ITT-E- Continuation Population with available on-treatment genotypic resistance data in the Continuation Phase.
| Participants | Participants Receiving DTG-Continuation Phase |
|---|---|
| INSTI | 5 |
| NRTI | 2 |
| PI | 0 |
Number of participants with fold change in treatment-emergent phenotypic resistance from Baseline to DTG, LPV/RTV was counted to assess the development of viral resistance. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-dose visit value minus Baseline value. Change in grade 0 to \>2 from Baseline is presented. Analysis was performed on viral phenotypic Population, which comprised of all participants in the ITT-E Population with available On-treatment phenotypic resistance data at the time confirmed virologic withdrawal criterion is met during Randomized Phase.
| Participants | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| DTG; <1; n=11, 23 | 5 | 18 |
| DTG; 1-<2; n=11, 23 | 2 | 5 |
| DTG; 2-<4; n=11, 23 | 1 | 0 |
| DTG; 4-<8; n=11, 23 | 0 | 0 |
| DTG; >=8; n=11, 23 | 3 | 0 |
| LPV/RTV; <1; n=11, 29 | 7 | 21 |
| LPV/RTV; 1-<2; n=11, 29 | 4 | 8 |
| LPV/RTV; 2-<4; n=11, 29 | 0 | 0 |
| LPV/RTV; 4-<8; n=11, 29 | 0 | 0 |
| LPV/RTV; >=8; n=11, 29 | 0 | 0 |
Number of participants with fold change in treatment-emergent phenotypic resistance from Baseline to DTG was counted to assess the development of viral resistance. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-dose visit value minus Baseline value. Change in grade 0 to \>2 from Baseline is presented. Analysis was performed on Viral Phenotypic Continuation Population which comprises all participants in the ITT-E- Continuation Population with available on-treatment phenotypic resistance data in the Continuation Phase.
| Participants | Participants Receiving DTG in Continuation Phase |
|---|---|
| DTG; <1 | 8 |
| DTG; 1-<2 | 3 |
| DTG; 2-<4 | 0 |
| DTG; 4-<8 | 0 |
| DTG; >=8 | 4 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, other situations as per medical or scientific judgment and is associated with liver injury or impaired liver function. Safety Population was used which comprised of all participants who received at least one dose of study treatment. Adverse events which were not Serious were considered as Non-Serious adverse events.
| Participants | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Any non-serious AEs | 155 | 202 |
| Any SAEs | 20 | 20 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, other situations as per medical or scientific judgment and is associated with liver injury or impaired liver function. Adverse events which were not Serious were considered as non-serious AEs.
| Participants | Participants Receiving DTG-Continuation Phase |
|---|---|
| Any non-serious AEs | 150 |
| Any SAEs | 29 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, other situations as per medical or scientific judgment and is associated with liver injury or impaired liver function. Adverse events which were not Serious were considered as non-serious AEs.
| Participants | DTG- Randomized Phase Followed by Continuation Phase | LPV/RTV- Randomized Phase Followed by DTG-Continuation Phase |
|---|---|---|
| Any non-serious AEs | 218 | 213 |
| Any SAEs | 47 | 20 |
Blood samples were collected from participants to evaluate clinical chemistry parameters including glucose, chloride, carbon-di-oxide (CO2), potassium, phosphate, sodium, urea, cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides. Lipid parameters were evaluated in fasting condition. Change from Baseline in clinical chemistry parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
| Millimoles per liter | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Glucose; Week 4; n= 279, 277 | 0.07 ± 0.789 | 0.01 ± 0.661 |
| Glucose; Week 8; n= 273, 271 | 0.08 ± 1.086 | -0.00 ± 0.914 |
| Glucose; Week 16; n= 280, 275 | 0.07 ± 0.740 | -0.06 ± 1.060 |
| Glucose; Week 24; n= 288, 276 | 0.22 ± 2.286 | -0.04 ± 1.037 |
| Glucose; Week 36; n= 270, 257 | 0.18 ± 1.056 | -0.01 ± 1.176 |
| Glucose; Week 48; n= 269, 237 | 0.12 ± 1.099 | -0.01 ± 1.028 |
| Glucose; Week 52; n= 258, 221 | 0.16 ± 1.142 | -0.01 ± 1.443 |
| Chloride; Week 4; n= 306, 302 | -0.20 ± 2.692 | -0.96 ± 2.751 |
| Chloride; Week 8; n= 301, 298 | -0.15 ± 2.752 | -1.00 ± 2.833 |
| Chloride; Week 16; n= 294, 292 | 0.04 ± 2.709 | -0.78 ± 2.773 |
| Chloride; Week 24; n= 295, 286 | -0.17 ± 2.887 | -0.67 ± 2.818 |
| Chloride; Week 36; n= 289, 276 | -0.18 ± 2.569 | -0.51 ± 2.880 |
| Chloride; Week 48; n= 278, 247 | -0.03 ± 2.663 | -0.81 ± 2.441 |
| Chloride; Week 52; n= 276, 238 | 0.06 ± 3.111 | -0.38 ± 2.739 |
| CO2; Week 4; n= 306, 302 | 0.12 ± 2.754 | -0.22 ± 2.650 |
| CO2; Week 8; n= 301, 297 | -0.01 ± 2.695 | -0.09 ± 2.564 |
| CO2; Week 16; n= 294, 292 | 0.21 ± 2.978 | 0.04 ± 2.638 |
| CO2; Week 24; n= 295, 286 | 0.13 ± 2.818 | -0.08 ± 2.777 |
| CO2; Week 36; n= 289, 276 | 0.16 ± 2.620 | -0.12 ± 2.861 |
| CO2; Week 48; n= 278, 247 | 0.06 ± 2.672 | 0.28 ± 2.867 |
| CO2; Week 52; n= 276, 238 | 0.04 ± 2.736 | 0.12 ± 2.555 |
| Potassium; Week 4; n= 306, 302 | 0.07 ± 0.373 | -0.02 ± 0.432 |
| Potassium; Week 8; n= 301, 297 | 0.09 ± 0.350 | 0.00 ± 0.428 |
| Potassium; Week 16; n= 294, 292 | 0.10 ± 0.375 | 0.03 ± 0.443 |
| Potassium; Week 24; n= 295, 286 | 0.11 ± 0.401 | 0.03 ± 0.433 |
| Potassium; Week 36; n= 289, 276 | 0.08 ± 0.363 | -0.03 ± 0.417 |
| Potassium; Week 48; n= 278, 247 | 0.07 ± 0.369 | 0.05 ± 0.423 |
| Potassium; Week 52; n= 276, 238 | 0.11 ± 0.412 | 0.04 ± 0.416 |
| Phosphate; Week 4; n= 306, 302 | 0.11 ± 0.188 | 0.01 ± 0.206 |
| Phosphate; Week 8; n= 301, 298 | 0.11 ± 0.182 | 0.03 ± 0.187 |
| Phosphate; Week 16; n= 294, 292 | 0.10 ± 0.180 | 0.03 ± 0.193 |
| Phosphate; Week 24; n= 295, 286 | 0.11 ± 0.174 | 0.03 ± 0.200 |
| Phosphate; Week 36; n= 289, 276 | 0.08 ± 0.196 | 0.01 ± 0.217 |
| Phosphate; Week 48; n= 278, 247 | 0.06 ± 0.193 | 0.03 ± 0.209 |
| Phosphate; Week 52; n= 276, 238 | 0.06 ± 0.203 | 0.01 ± 0.197 |
| Sodium; Week 4; n= 306, 302 | -0.20 ± 2.393 | -0.80 ± 2.284 |
| Sodium; Week 8; n= 301, 298 | -0.12 ± 2.420 | -0.87 ± 2.569 |
| Sodium; Week 16; n= 294, 292 | 0.29 ± 2.364 | -0.58 ± 2.449 |
| Sodium; Week 24; n= 295, 286 | -0.07 ± 2.472 | -0.53 ± 2.446 |
| Sodium; Week 36; n= 289, 276 | 0.08 ± 2.375 | -0.51 ± 2.410 |
| Sodium; Week 48; n= 278, 247 | 0.22 ± 2.277 | -0.62 ± 2.505 |
| Sodium; Week 52; n= 276, 238 | 0.09 ± 2.886 | -0.37 ± 2.402 |
| Urea; Week 4; n= 306, 302 | 0.21 ± 1.658 | 0.18 ± 1.253 |
| Urea; Week 8; n= 301, 298 | 0.21 ± 1.214 | 0.23 ± 1.205 |
| Urea; Week 16; n= 294, 292 | 0.25 ± 1.269 | 0.29 ± 1.344 |
| Urea; Week 24; n= 295, 286 | 0.35 ± 1.236 | 0.17 ± 1.308 |
| Urea; Week 36; n= 289, 276 | 0.11 ± 1.165 | 0.20 ± 1.284 |
| Urea; Week 48; n= 278, 247 | 0.19 ± 1.260 | 0.18 ± 1.241 |
| Urea; Week 52; n= 276, 238 | 0.30 ± 1.482 | 0.32 ± 1.311 |
| Cholesterol; Week 4; n= 4, 6 | -0.88 ± 1.081 | 1.22 ± 1.963 |
| Cholesterol; Week 8; n= 7, 10 | -0.37 ± 1.158 | 1.04 ± 1.577 |
| Cholesterol; Week 16; n= 270, 261 | -0.22 ± 0.878 | 0.31 ± 0.872 |
| Cholesterol; Week 24; n= 280, 271 | -0.23 ± 0.760 | 0.29 ± 0.934 |
| Cholesterol; Week 36; n= 283, 272 | -0.24 ± 0.789 | 0.28 ± 0.901 |
| Cholesterol; Week 48; n= 276, 272 | -0.10 ± 0.808 | 0.38 ± 0.946 |
| Cholesterol; Week 52; n= 7, 6 | 0.35 ± 0.593 | -0.18 ± 0.850 |
| HDL cholesterol; Week 4; n= 4, 6 | -0.18 ± 0.197 | 0.10 ± 0.191 |
| HDL cholesterol; Week 8; n= 7,10 | -0.01 ± 0.262 | 0.08 ± 0.363 |
| HDL cholesterol; Week 16; n= 270, 261 | -0.02 ± 0.300 | -0.00 ± 0.341 |
| HDL cholesterol; Week 24; n= 280, 271 | -0.02 ± 0.319 | 0.00 ± 0.339 |
| HDL cholesterol; Week 36; n= 283, 272 | -0.02 ± 0.319 | 0.00 ± 0.340 |
| HDL cholesterol; Week 48; n= 276, 272 | -0.02 ± 0.298 | 0.03 ± 0.353 |
| HDL cholesterol; Week 52; n= 7,6 | 0.18 ± 0.327 | 0.13 ± 0.327 |
| LDL cholesterol; Week 4; n= 4, 3 | -0.29 ± 1.157 | -0.17 ± 0.398 |
| LDL cholesterol; Week 8; n= 7, 8 | -0.09 ± 0.911 | 0.50 ± 0.720 |
| LDL cholesterol; Week 16; n= 259, 246 | -0.10 ± 0.674 | 0.06 ± 0.644 |
| LDL cholesterol; Week 24; n= 272, 261 | -0.10 ± 0.601 | 0.05 ± 0.652 |
| LDL cholesterol; Week 36; n= 274, 261 | -0.11 ± 0.606 | 0.05 ± 0.659 |
| LDL cholesterol; Week 48; n= 269, 264 | -0.01 ± 0.633 | 0.11 ± 0.682 |
| LDL cholesterol; Week 52; n= 7, 6 | 0.06 ± 0.511 | -0.25 ± 0.857 |
| Triglycerides; Week 4; n= 4, 6 | -0.89 ± 0.852 | 4.23 ± 5.773 |
| Triglycerides; Week 8; n= 7, 10 | -0.57 ± 1.153 | 1.95 ± 5.131 |
| Triglycerides; Week 16; n= 270, 261 | -0.32 ± 1.131 | 0.63 ± 1.289 |
| Triglycerides; Week 24; n= 280, 271 | -0.32 ± 0.997 | 0.67 ± 1.826 |
| Triglycerides; Week 36; n= 283, 272 | -0.31 ± 1.289 | 0.61 ± 1.497 |
| Triglycerides; Week 48; n= 276, 272 | -0.24 ± 1.120 | 0.57 ± 1.488 |
| Triglycerides; Week 52; n= 7, 6 | 0.22 ± 0.769 | -0.15 ± 0.259 |
Blood samples were collected from participants to evaluate clinical chemistry parameters including ALP, ALT, AST and creatine kinase. Change from Baseline in clinical chemistry parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
| International unit per liter | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| ALP; Week 4; n= 306, 302 | -12.24 ± 21.900 | -14.94 ± 22.979 |
| ALP; Week 8; n= 301, 298 | -13.73 ± 26.135 | -13.46 ± 29.998 |
| ALP; Week 16; n= 294, 292 | -13.87 ± 31.452 | -11.38 ± 26.190 |
| ALP; Week 24; n= 295, 286 | -14.19 ± 27.800 | -6.06 ± 50.943 |
| ALP; Week 36; n= 289, 276 | -13.53 ± 28.875 | -7.85 ± 30.394 |
| ALP; Week 48; n= 278, 247 | -14.10 ± 28.935 | -6.87 ± 32.071 |
| ALP; Week 52; n= 276, 238 | -13.81 ± 29.317 | -7.23 ± 31.046 |
| ALT; Week 4; n= 306, 302 | -2.50 ± 17.285 | -10.25 ± 17.639 |
| ALT; Week 8; n= 301, 298 | -2.49 ± 19.222 | -9.04 ± 25.556 |
| ALT; Week 16; n= 294, 292 | -4.32 ± 18.502 | -8.59 ± 24.507 |
| ALT; Week 24; n= 295, 286 | -3.87 ± 20.108 | -9.20 ± 33.054 |
| ALT; Week 36; n= 289, 276 | -1.31 ± 25.356 | -11.16 ± 22.196 |
| ALT; Week 48; n= 278, 247 | 0.19 ± 39.985 | -6.47 ± 51.492 |
| ALT; Week 52; n= 276, 238 | -1.04 ± 23.232 | -10.63 ± 25.508 |
| AST; Week 4; n= 306, 302 | -3.56 ± 17.463 | -7.68 ± 13.654 |
| AST; Week 8; n= 301, 297 | -2.89 ± 17.934 | -6.64 ± 21.295 |
| AST; Week 16; n= 294, 292 | -4.70 ± 17.445 | -6.49 ± 18.143 |
| AST; Week 24; n= 295, 286 | -3.83 ± 17.713 | -6.45 ± 28.933 |
| AST; Week 36; n= 289, 276 | -1.76 ± 22.437 | -8.36 ± 21.550 |
| AST; Week 48; n= 278, 247 | -2.03 ± 28.194 | -6.43 ± 27.155 |
| AST; Week 52; n= 276, 238 | -1.51 ± 22.645 | -7.55 ± 28.125 |
| Creatine kinase; Week 4; n= 306, 302 | -2.85 ± 215.820 | -15.59 ± 106.738 |
| Creatine kinase; Week 8; n= 301, 298 | 18.61 ± 312.940 | -10.42 ± 128.109 |
| Creatine kinase; Week 16; n= 294, 292 | 11.75 ± 180.905 | 11.62 ± 203.660 |
| Creatine kinase; Week 24; n= 295, 286 | 34.71 ± 312.173 | -0.28 ± 186.927 |
| Creatine kinase; Week 36; n= 289, 276 | 72.34 ± 892.830 | -5.08 ± 135.191 |
| Creatine kinase; Week 48; n= 278, 247 | 45.50 ± 451.135 | 16.52 ± 295.891 |
| Creatine kinase; Week 52; n= 276, 238 | 39.24 ± 228.026 | 54.97 ± 628.621 |
Blood samples were collected from participants to evaluate clinical chemistry parameter including albumin. Change from Baseline in clinical chemistry parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
| Gram per liter | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Week 4; n= 306, 302 | -0.39 ± 2.554 | -0.51 ± 2.670 |
| Week 8; n= 301, 298 | 0.09 ± 2.792 | -0.67 ± 2.828 |
| Week 16; n= 294, 292 | 0.50 ± 3.148 | -0.28 ± 3.062 |
| Week 24; n= 295, 286 | 0.63 ± 3.326 | -0.06 ± 3.207 |
| Week 36; n= 289, 276 | 0.76 ± 3.479 | -0.11 ± 3.091 |
| Week 48; n= 278, 247 | 0.71 ± 3.250 | 0.11 ± 2.912 |
| Week 52; n= 276, 238 | 0.83 ± 3.605 | -0.15 ± 3.142 |
Blood samples were collected from participants to evaluate clinical chemistry parameters including creatinine and bilirubin. Change from Baseline in clinical chemistry parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
| Micromoles per liter | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Creatinine; Week 4; n= 306, 302 | 9.68 ± 9.308 | 4.69 ± 8.575 |
| Creatinine; Week 8; n= 301, 298 | 10.81 ± 8.414 | 5.57 ± 9.214 |
| Creatinine; Week 16; n= 294, 292 | 12.46 ± 9.065 | 5.19 ± 9.648 |
| Creatinine; Week 24; n= 295, 286 | 12.96 ± 10.248 | 5.75 ± 11.606 |
| Creatinine; Week 36; n= 289, 276 | 12.08 ± 9.667 | 5.98 ± 14.737 |
| Creatinine; Week 48; n= 278, 247 | 12.92 ± 9.412 | 6.15 ± 13.373 |
| Creatinine; Week 52; n= 276, 238 | 13.22 ± 10.229 | 6.15 ± 12.268 |
| Bilirubin; Week 4; n= 305, 301 | 1.74 ± 4.982 | 3.39 ± 3.997 |
| Bilirubin; Week 8; n= 301, 297 | 2.25 ± 4.344 | 3.76 ± 5.291 |
| Bilirubin; Week 16; n= 294, 292 | 2.79 ± 4.547 | 3.97 ± 4.957 |
| Bilirubin; Week 24; n= 295, 285 | 3.28 ± 4.692 | 4.15 ± 5.422 |
| Bilirubin; Week 36; n= 289, 275 | 3.26 ± 4.925 | 4.43 ± 5.447 |
| Bilirubin; Week 48; n= 278, 246 | 3.19 ± 4.288 | 4.82 ± 5.552 |
| Bilirubin; Week 52; n= 276, 238 | 3.54 ± 5.231 | 4.26 ± 4.644 |
Blood samples were collected from participants to evaluate clinical chemistry parameter including lipase. Change from Baseline in lipase at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
| Unit per liter | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Week 4; n= 303, 301 | 0.17 ± 11.082 | 1.52 ± 15.067 |
| Week 8; n= 299, 298 | 0.79 ± 13.422 | 0.58 ± 10.558 |
| Week 16; n= 292, 293 | 2.01 ± 17.174 | 0.94 ± 11.197 |
| Week 24; n= 295, 284 | 1.19 ± 15.984 | 1.14 ± 13.770 |
| Week 36; n= 287, 275 | 0.49 ± 15.089 | 0.11 ± 11.570 |
| Week 48; n= 278, 247 | 1.13 ± 14.673 | 1.68 ± 12.783 |
| Week 52; n= 275, 237 | 3.18 ± 22.215 | 1.59 ± 11.117 |
Number of participants with clinical chemistry toxicities has been presented. Toxicities were based on the Division of AIDS (DAIDS) grading system. Grade 1=Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Potentially life-threatening. Higher the grade, more severe the symptoms. Lipids and glucose parameters were summarized on fasting data. Data has been reported for clinical chemistry parameters including serum glucose, ALT, Albumin, ALP, AST, Bilirubin, CO2, Creatine kinase, LDL cholesterol calculation, LDL cholesterol direct, Lipase, Phosphate, Potassium, Sodium, Cholesterol, Creatinine and Serum Triglycerides.
| Participants | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Serum glucose; Grade 1 | 32 | 27 |
| Serum glucose; Grade 2 | 10 | 15 |
| Serum glucose; Grade 3 | 4 | 1 |
| Serum glucose; Grade 4 | 1 | 0 |
| ALT; Grade 1 | 27 | 13 |
| ALT; Grade 2 | 9 | 6 |
| ALT; Grade 3 | 3 | 2 |
| ALT; Grade 4 | 1 | 0 |
| Albumin; Grade 1 | 7 | 3 |
| Albumin; Grade 2 | 4 | 0 |
| Albumin; Grade 3 | 0 | 0 |
| Albumin; Grade 4 | 0 | 0 |
| ALP; Grade 1 | 9 | 22 |
| ALP; Grade 2 | 4 | 1 |
| ALP; Grade 3 | 0 | 1 |
| ALP; Grade 4 | 0 | 0 |
| AST; Grade 1 | 29 | 18 |
| AST; Grade 2 | 10 | 4 |
| AST; Grade 3 | 2 | 5 |
| AST; Grade 4 | 1 | 0 |
| Bilirubin; Grade 1 | 14 | 21 |
| Bilirubin; Grade 2 | 3 | 11 |
| Bilirubin; Grade 3 | 2 | 0 |
| Bilirubin; Grade 4 | 0 | 0 |
| CO2; Grade 1 | 99 | 105 |
| CO2; Grade 2 | 24 | 13 |
| CO2; Grade 3 | 1 | 0 |
| CO2; Grade 4 | 0 | 0 |
| Creatine kinase; Grade 1 | 13 | 6 |
| Creatine kinase; Grade 2 | 2 | 3 |
| Creatine kinase; Grade 3 | 5 | 3 |
| Creatine kinase; Grade 4 | 3 | 1 |
| LDL cholesterol calculation; Grade 1 | 17 | 20 |
| LDL cholesterol calculation; Grade 2 | 4 | 16 |
| LDL cholesterol calculation; Grade 3 | 1 | 4 |
| LDL cholesterol calculation; Grade 4 | 0 | 0 |
| LDL cholesterol direct; Grade 1 | 3 | 8 |
| LDL cholesterol direct; Grade 2 | 2 | 4 |
| LDL cholesterol direct; Grade 3 | 0 | 1 |
| LDL cholesterol direct; Grade 4 | 0 | 0 |
| Lipase; Grade 1 | 16 | 12 |
| Lipase; Grade 2 | 6 | 5 |
| Lipase; Grade 3 | 1 | 1 |
| Lipase; Grade 4 | 2 | 0 |
| Phosphate; Grade 1 | 7 | 6 |
| Phosphate; Grade 2 | 15 | 42 |
| Phosphate; Grade 3 | 5 | 8 |
| Phosphate; Grade 4 | 0 | 0 |
| Potassium; Grade 1 | 16 | 20 |
| Potassium; Grade 2 | 1 | 1 |
| Potassium; Grade 3 | 2 | 3 |
| Potassium; Grade 4 | 1 | 1 |
| Sodium; Grade 1 | 76 | 117 |
| Sodium; Grade 2 | 5 | 2 |
| Sodium; Grade 3 | 1 | 0 |
| Sodium; Grade 4 | 1 | 0 |
| Cholesterol; Grade 1 | 14 | 46 |
| Cholesterol; Grade 2 | 5 | 32 |
| Cholesterol; Grade 3 | 3 | 4 |
| Cholesterol; Grade 4 | 0 | 0 |
| Creatinine; Grade 1 | 1 | 4 |
| Creatinine; Grade 2 | 2 | 5 |
| Creatinine; Grade 3 | 0 | 0 |
| Creatinine; Grade 4 | 0 | 0 |
| Serum Triglycerides; Grade 1 | 0 | 0 |
| Serum Triglycerides; Grade 2 | 1 | 11 |
| Serum Triglycerides; Grade 3 | 1 | 3 |
| Serum Triglycerides; Grade 4 | 1 | 2 |
Number of participants with clinical chemistry toxicities has been presented. Toxicities were based on the Division of AIDS (DAIDS) grading system. Grade 1=Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Potentially life-threatening. Higher the grade, more severe the symptoms. Lipids and glucose parameters were summarized on fasting data. Data has been reported for clinical chemistry parameters including serum glucose, ALT, Albumin, ALP, AST, Bilirubin, CO2, Creatine kinase, LDL cholesterol calculation, LDL cholesterol direct, Lipase, Phosphate, Potassium, Sodium, Cholesterol, Creatinine and Serum Triglycerides.
| Participants | Participants Receiving DTG in Continuation Phase |
|---|---|
| Serum glucose; Grade 1 | 43 |
| Serum glucose; Grade 2 | 33 |
| Serum glucose; Grade 3 | 9 |
| Serum glucose; Grade 4 | 0 |
| ALT; Grade 1 | 46 |
| ALT; Grade 2 | 16 |
| ALT; Grade 3 | 2 |
| ALT; Grade 4 | 0 |
| Albumin; Grade 1 | 1 |
| Albumin; Grade 2 | 4 |
| Albumin; Grade 3 | 0 |
| Albumin; Grade 4 | 0 |
| ALP; Grade 1 | 13 |
| ALP; Grade 2 | 2 |
| ALP; Grade 3 | 0 |
| ALP; Grade 4 | 0 |
| AST; Grade 1 | 37 |
| AST; Grade 2 | 11 |
| AST; Grade 3 | 5 |
| AST; Grade 4 | 1 |
| Bilirubin; Grade 1 | 14 |
| Bilirubin; Grade 2 | 9 |
| Bilirubin; Grade 3 | 0 |
| Bilirubin; Grade 4 | 2 |
| CO2; Grade 1 | 83 |
| CO2; Grade 2 | 20 |
| CO2; Grade 3 | 0 |
| CO2; Grade 4 | 0 |
| Creatine kinase; Grade 1 | 24 |
| Creatine kinase; Grade 2 | 6 |
| Creatine kinase; Grade 3 | 5 |
| Creatine kinase; Grade 4 | 5 |
| LDL cholesterol calculation; Grade 1 | 1 |
| LDL cholesterol calculation; Grade 2 | 1 |
| LDL cholesterol calculation; Grade 3 | 0 |
| LDL cholesterol calculation; Grade 4 | 0 |
| LDL cholesterol direct; Grade 1 | 1 |
| LDL cholesterol direct; Grade 2 | 1 |
| LDL cholesterol direct; Grade 3 | 0 |
| LDL cholesterol direct; Grade 4 | 0 |
| Lipase; Grade 1 | 19 |
| Lipase; Grade 2 | 9 |
| Lipase; Grade 3 | 2 |
| Lipase; Grade 4 | 4 |
| Phosphate; Grade 1 | 16 |
| Phosphate; Grade 2 | 38 |
| Phosphate; Grade 3 | 6 |
| Phosphate; Grade 4 | 0 |
| Potassium; Grade 1 | 24 |
| Potassium; Grade 2 | 5 |
| Potassium; Grade 3 | 1 |
| Potassium; Grade 4 | 1 |
| Sodium; Grade 1 | 69 |
| Sodium; Grade 2 | 0 |
| Sodium; Grade 3 | 0 |
| Sodium; Grade 4 | 0 |
| Cholesterol; Grade 1 | 1 |
| Cholesterol; Grade 2 | 0 |
| Cholesterol; Grade 3 | 1 |
| Cholesterol; Grade 4 | 0 |
| Creatinine; Grade 1 | 7 |
| Creatinine; Grade 2 | 4 |
| Creatinine; Grade 3 | 0 |
| Creatinine; Grade 4 | 0 |
| Serum Triglycerides; Grade 1 | 0 |
| Serum Triglycerides; Grade 2 | 0 |
| Serum Triglycerides; Grade 3 | 0 |
| Serum Triglycerides; Grade 4 | 1 |
Blood samples were collected from participants to evaluate clinical hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Change from Baseline in clinical hematology parameters at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
| 10^9 cells/liter | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Basophil; Week 4; n= 289, 291 | 0.00 ± 0.029 | 0.00 ± 0.016 |
| Basophil; Week 8; n= 296, 289 | 0.00 ± 0.017 | 0.00 ± 0.017 |
| Basophil; Week 16; n= 286, 286 | 0.00 ± 0.017 | 0.00 ± 0.017 |
| Basophil; Week 24; n= 290, 281 | 0.01 ± 0.017 | 0.00 ± 0.017 |
| Basophil; Week 36; n= 283, 275 | 0.01 ± 0.021 | 0.00 ± 0.018 |
| Basophil; Week 48; n= 266, 242 | 0.01 ± 0.021 | 0.01 ± 0.019 |
| Basophil; Week 52; n= 265, 229 | 0.01 ± 0.018 | 0.01 ± 0.022 |
| Eosinophil; Week 4; n= 290, 291 | 0.02 ± 0.182 | 0.02 ± 0.287 |
| Eosinophil; Week 8; n= 296, 289 | 0.03 ± 0.281 | 0.01 ± 0.175 |
| Eosinophil; Week 16; n= 286, 286 | 0.01 ± 0.240 | 0.01 ± 0.201 |
| Eosinophil; Week 24; n= 290, 281 | 0.02 ± 0.188 | 0.01 ± 0.173 |
| Eosinophil; Week 36; n= 283, 275 | 0.04 ± 0.214 | 0.02 ± 0.192 |
| Eosinophil; Week 48; n= 266, 242 | 0.04 ± 0.267 | 0.01 ± 0.210 |
| Eosinophil; Week 52; n= 265, 229 | 0.02 ± 0.188 | 0.01 ± 0.217 |
| Lymphocyte; Week 4; n= 289, 291 | 0.13 ± 0.519 | 0.10 ± 0.549 |
| Lymphocyte; Week 8; n= 296, 289 | 0.23 ± 0.592 | 0.29 ± 0.651 |
| Lymphocyte; Week 16; n= 286, 286 | 0.28 ± 0.611 | 0.29 ± 0.668 |
| Lymphocyte; Week 24; n= 290, 281 | 0.31 ± 0.589 | 0.34 ± 0.625 |
| Lymphocyte; Week 36; n= 283, 275 | 0.38 ± 0.595 | 0.35 ± 0.646 |
| Lymphocyte; Week 48; n= 266, 242 | 0.38 ± 0.648 | 0.37 ± 0.697 |
| Lymphocyte; Week 52; n= 265, 229 | 0.34 ± 0.716 | 0.39 ± 0.720 |
| Monocyte; Week 4; n= 289, 291 | 0.02 ± 0.201 | 0.00 ± 0.167 |
| Monocyte; Week 8; n= 296, 289 | 0.01 ± 0.159 | 0.02 ± 0.174 |
| Monocyte; Week 16; n= 286, 286 | -0.00 ± 0.140 | 0.01 ± 0.154 |
| Monocyte; Week 24; n= 290, 281 | -0.01 ± 0.139 | 0.01 ± 0.173 |
| Monocyte; Week 36; n= 283, 275 | 0.01 ± 0.151 | 0.02 ± 0.175 |
| Monocyte; Week 48; n= 266, 242 | 0.01 ± 0.157 | 0.03 ± 0.190 |
| Monocyte; Week 52; n= 265, 229 | 0.01 ± 0.173 | 0.02 ± 0.205 |
| Neutrophil; Week 4; n= 289, 291 | 0.35 ± 1.914 | 0.23 ± 1.407 |
| Neutrophil; Week 8; n= 296, 289 | 0.27 ± 1.491 | 0.23 ± 1.678 |
| Neutrophil; Week 16; n= 286, 286 | 0.31 ± 1.462 | 0.29 ± 1.481 |
| Neutrophil; Week 24; n= 290, 281 | 0.42 ± 1.694 | 0.34 ± 1.315 |
| Neutrophil; Week 36; n= 283, 275 | 0.50 ± 1.605 | 0.37 ± 1.661 |
| Neutrophil; Week 48; n= 266, 242 | 0.46 ± 1.491 | 0.50 ± 1.449 |
| Neutrophil; Week 52; n= 265, 229 | 0.63 ± 1.691 | 0.44 ± 1.604 |
| Platelet; Week 4; n= 291, 293 | 22.81 ± 63.368 | 23.64 ± 53.514 |
| Platelet; Week 8; n= 293, 293 | 22.95 ± 62.969 | 26.17 ± 58.634 |
| Platelet; Week 16; n= 287, 286 | 21.77 ± 66.974 | 28.03 ± 61.780 |
| Platelet; Week 24; n= 290, 282 | 19.79 ± 63.702 | 27.32 ± 65.103 |
| Platelet; Week 36; n= 283, 274 | 20.02 ± 69.570 | 21.41 ± 64.787 |
| Platelet; Week 48; n= 265, 246 | 16.72 ± 66.983 | 30.20 ± 63.038 |
| Platelet; Week 52; n= 267, 232 | 20.98 ± 66.402 | 32.60 ± 71.882 |
| Leukocyte; Week 4; n= 289, 292 | 0.51 ± 2.105 | 0.37 ± 1.607 |
| Leukocyte; Week 8; n= 296, 292 | 0.54 ± 1.676 | 0.54 ± 1.879 |
| Leukocyte; Week 16; n= 290, 288 | 0.61 ± 1.622 | 0.60 ± 1.746 |
| Leukocyte; Week 24; n= 291, 284 | 0.75 ± 1.826 | 0.70 ± 1.545 |
| Leukocyte; Week 36; n= 285, 276 | 0.91 ± 1.777 | 0.76 ± 1.913 |
| Leukocyte; Week 48; n= 267, 245 | 0.91 ± 1.777 | 0.90 ± 1.718 |
| Leukocyte; Week 52; 268, 231 | 0.99 ± 1.908 | 0.86 ± 1.819 |
Blood samples were collected from participants to evaluate clinical hematology parameter including hematocrit. Change from Baseline in hematocrit values at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
| Proportion of red blood cells in blood | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Week 4; n= 296, 296 | -0.00 ± 0.032 | -0.01 ± 0.029 |
| Week 8; n= 297, 294 | 0.00 ± 0.039 | -0.01 ± 0.037 |
| Week 16; n= 290, 289 | 0.01 ± 0.044 | -0.01 ± 0.042 |
| Week 24; n= 291, 285 | 0.01 ± 0.037 | -0.00 ± 0.039 |
| Week 36; n= 286, 276 | 0.01 ± 0.038 | -0.00 ± 0.039 |
| Week 48; n= 268, 248 | 0.02 ± 0.038 | -0.00 ± 0.041 |
| Week 52; n= 269, 233 | 0.02 ± 0.040 | -0.00 ± 0.041 |
Blood samples were collected from participants to evaluate clinical hematology parameter including hemoglobin. Change from Baseline in hemoglobin values at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
| Gram per liter | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Week 4; n= 296, 296 | -1.33 ± 9.858 | -4.23 ± 8.994 |
| Week 8; n= 297, 294 | -0.12 ± 11.725 | -4.41 ± 11.340 |
| Week 16; n= 290, 289 | 2.39 ± 12.905 | -2.10 ± 12.904 |
| Week 24; n= 291, 285 | 3.05 ± 10.881 | -0.46 ± 12.363 |
| Week 36; n= 286, 276 | 5.18 ± 11.968 | 0.34 ± 12.628 |
| Week 48; n= 268, 248 | 6.05 ± 12.138 | 0.90 ± 13.486 |
| Week 52; n= 269, 233 | 5.68 ± 12.457 | 1.07 ± 13.361 |
Blood samples were collected from participants to evaluate clinical hematology parameter including MCV. Change from Baseline in MCV values at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
| Femtoliter | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Week 4; n= 296, 296 | 0.68 ± 3.820 | 0.46 ± 3.799 |
| Week 8; n= 297, 294 | 1.72 ± 7.659 | 1.78 ± 7.266 |
| Week 16; n= 290, 289 | 3.91 ± 13.827 | 3.83 ± 13.600 |
| Week 24; n= 291, 285 | 4.86 ± 15.279 | 4.39 ± 15.099 |
| Week 36; n= 286, 276 | 4.33 ± 15.450 | 4.62 ± 15.413 |
| Week 48; n= 268, 248 | 4.14 ± 15.637 | 4.79 ± 15.463 |
| Week 52; n= 269, 233 | 4.36 ± 15.496 | 4.72 ± 15.697 |
Blood samples were collected from participants to evaluate clinical hematology parameter including erythrocyte. Change from Baseline in erythrocyte values at Weeks 4, 8, 16, 24, 36, 48, 52 are presented. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value.
| 10^12 cells/liter | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Week 4; n= 296, 296 | -0.08 ± 0.385 | -0.16 ± 0.363 |
| Week 8; n= 297, 294 | -0.07 ± 0.558 | -0.23 ± 0.529 |
| Week 16; n= 290, 289 | -0.06 ± 0.808 | -0.21 ± 0.754 |
| Week 24; n= 291, 285 | -0.08 ± 0.768 | -0.20 ± 0.747 |
| Week 36; n= 286, 276 | -0.01 ± 0.792 | -0.18 ± 0.749 |
| Week 48; n= 268, 248 | 0.01 ± 0.798 | -0.18 ± 0.750 |
| Week 52; n= 269, 233 | -0.01 ± 0.788 | -0.17 ± 0.761 |
Number of participants with hematology toxicities has been presented. Toxicities were based on the Division of AIDS (DAIDS) grading system. Grade 1=Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Potentially life-threatening. Higher the grade, more severe the symptoms. Data has been reported for hematology parameters including Hemoglobin, Leukocytes, Neutrophils and Platelets.
| Participants | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Hemoglobin; Grade 1 | 6 | 18 |
| Hemoglobin; Grade 2 | 5 | 4 |
| Hemoglobin; Grade 3 | 5 | 0 |
| Hemoglobin; Grade 4 | 4 | 1 |
| Leukocytes; Grade 1 | 19 | 10 |
| Leukocytes; Grade 2 | 5 | 5 |
| Leukocytes; Grade 3 | 3 | 0 |
| Leukocytes; Grade 4 | 0 | 0 |
| Neutrophils; Grade 1 | 25 | 26 |
| Neutrophils; Grade 2 | 9 | 11 |
| Neutrophils; Grade 3 | 10 | 3 |
| Neutrophils; Grade 4 | 4 | 0 |
| Platelets; Grade 1 | 6 | 4 |
| Platelets; Grade 2 | 2 | 7 |
| Platelets; Grade 3 | 0 | 1 |
| Platelets; Grade 4 | 1 | 0 |
Number of participants with hematology toxicities has been presented. Toxicities were based on the Division of AIDS (DAIDS) grading system. Grade 1=Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Potentially life-threatening. Higher the grade, more severe the symptoms. Data has been reported for hematology parameters including Hemoglobin, Leukocytes, Neutrophils and Platelets.
| Participants | Participants Receiving DTG in Continuation Phase |
|---|---|
| Hemoglobin; Grade 1 | 13 |
| Hemoglobin; Grade 2 | 2 |
| Hemoglobin; Grade 3 | 1 |
| Hemoglobin; Grade 4 | 0 |
| Leukocytes; Grade 1 | 23 |
| Leukocytes; Grade 2 | 6 |
| Leukocytes; Grade 3 | 0 |
| Leukocytes; Grade 4 | 0 |
| Neutrophils; Grade 1 | 21 |
| Neutrophils; Grade 2 | 16 |
| Neutrophils; Grade 3 | 10 |
| Neutrophils; Grade 4 | 2 |
| Platelets; Grade 1 | 6 |
| Platelets; Grade 2 | 3 |
| Platelets; Grade 3 | 1 |
| Platelets; Grade 4 | 0 |
Number of participants who discontinued study treatment due to AEs or SAEs were summarized.
| Participants | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Number of Participants Who Discontinued Treatment Due to AEs-Randomized Phase | 8 | 18 |
Number of participants who discontinued study treatment due to AEs were summarized.
| Participants | Participants Receiving DTG in Continuation Phase |
|---|---|
| Number of Participants Who Discontinued Treatment Due to AEs-Continuation Phase | 9 |
Blood samples were collected from participants in fasting state to evaluate LDL cholesterol. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Analysis was performed using multiple imputation with missing at random assumption. Only participants available at the time of evaluation were analyzed.
| Millimoles per liter | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Week 24 | -0.121 ± 0.0356 | 0.050 ± 0.0378 |
| Week 48 | -0.012 ± 0.0387 | 0.135 ± 0.0416 |
Blood samples were collected from participants in fasting state to evaluate total cholesterol/HDL cholesterol ratio. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Only participants available at the time of evaluation were analyzed. Analysis was performed using multiple imputation with missing at random assumption.
| Ratio | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Week 24 | -0.237 ± 0.0662 | 0.305 ± 0.0683 |
| Week 48 | -0.084 ± 0.0693 | 0.275 ± 0.0729 |
Blood samples were collected from participants in fasting state at indicated time-points to evaluate LDL cholesterol. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Number of participants who experienced maximum grade 2 or greater toxicity post-Baseline in fasting LDL cholesterol was summarized. Participants were graded using the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening. Higher the grade, more severe the symptoms.
| Participants | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Number of Participants With Maximum Post-Baseline Emergent Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol | 5 | 20 |
Number of participants who experienced maximum grade 2 or greater toxicity post-Baseline in drug-related diarrhea was summarized. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. Participants were graded using the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events. Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=potentially life-threatening. Higher the grade, more severe the symptoms.
| Participants | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Week 24 | 1 | 22 |
| Week 48 | 1 | 23 |
The GSRS is a disease-specific instrument of 15 items combined into five symptom clusters depicting Reflux, Abdominal pain, Indigestion, Diarrhea and Constipation. The scale ranges from 1= no discomfort to 7= very severe discomfort for each symptom cluster. Higher scores show greater severity of symptoms. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. The analysis was performed using Last Observation Carried Forward (LOCF) dataset. In the LOCF dataset, missing values were carried forward from the previous, non-missing available on-treatment assessment.
| Scores on a scale | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Diarrhea Syndrome Score; Week 4; n= 303, 305 | 0.00 (-0.33 to 0.00) | 0.00 (0.00 to 1.33) |
| Diarrhea Syndrome Score; Week 24; n= 305, 306 | 0.00 (-0.33 to 0.00) | 0.00 (0.00 to 1.00) |
| Diarrhea Syndrome Score; Week 48; n= 305, 306 | 0.00 (-0.33 to 0.00) | 0.00 (0.00 to 0.67) |
| Indigestion Syndrome Score; Week 4; n=305, 306 | 0.00 (-0.25 to 0.00) | 0.00 (0.00 to 0.75) |
| Indigestion Syndrome Score; Week 24; n= 306, 307 | 0.00 (-0.25 to 0.00) | 0.00 (-0.25 to 0.50) |
| Indigestion Syndrome Score; Week 48; n= 306, 307 | 0.00 (-0.50 to 0.00) | 0.00 (-0.25 to 0.50) |
| Constipation Score; Week 4; n= 305, 305 | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.33) |
| Constipation Score; Week 24; n= 306, 306 | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.33) |
| Constipation Score; Week 48; n= 306, 306 | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.33) |
| Abdominal pain Score; Week 4; n= 305, 306 | 0.00 (-0.33 to 0.00) | 0.00 (0.00 to 0.67) |
| Abdominal pain Score; Week 24; n= 306, 307 | 0.00 (-0.33 to 0.00) | 0.00 (-0.33 to 0.67) |
| Abdominal pain Score; Week 48; n= 306, 307 | 0.00 (-0.67 to 0.00) | 0.00 (0.00 to 0.33) |
| Reflux Score; Week 4; n= 305, 306 | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.50) |
| Reflux Score; Week 24; n= 306, 307 | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Reflux Score; Week 48; n= 306, 307 | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.50) |
The HIVTSQ is a self-reported scales that measure overall satisfaction with treatment. The score ranges from 0-10. The higher the score, the greater the improvement in treatment satisfaction as compared to the past few weeks. A smaller score represents a decline in treatment satisfaction compared to the past few weeks. Baseline was defined as the latest pre-dose assessment value. Change from Baseline was calculated as post-Baseline visit values minus Baseline value. The analysis was performed using LOCF dataset. In the LOCF dataset, missing values were carried forward from the previous, non-missing available on-treatment assessment.
| Scores on a scale | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Week 4; n= 304, 306 | 3.4 (0.0 to 11.5) | 2.0 (0.0 to 10.0) |
| Week 24; n= 305, 307 | 5.0 (0.0 to 13.0) | 3.0 (0.0 to 12.0) |
| Week 48; n= 305, 307 | 5.0 (0.0 to 14.0) | 3.0 (0.0 to 11.0) |
Treatment compliance was evaluated through MMAS-8. It is an eight-item self-reported measure of medication-taking behavior. The score ranges from 0-8 where scores of 8 indicate high or near perfect adherence, and scores of less than 6 indicate poor or inadequate adherence on the MMAS-8 scale. Number of participants showing low, medium and high adherence to treatment are presented. Low adherence is a score 0-5.75, medium adherence is a score of 6-7.75 and high adherence is a score of 8. The analysis was performed using LOCF dataset. In the LOCF dataset, missing values were carried forward from the previous, non-missing available on-treatment assessment.
| Participants | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase |
|---|---|---|
| Baseline (Day 1, Pre-dose); low; n= 309, 312 | 70 | 75 |
| Baseline (Day 1, Pre-dose); medium; n= 309, 312 | 102 | 100 |
| Baseline (Day 1, Pre-dose); high; n= 309, 312 | 137 | 137 |
| Week 4; low; n= 306, 306 | 17 | 37 |
| Week 4; medium; n= 306, 306 | 81 | 80 |
| Week 4; high n= 306, 306 | 208 | 189 |
| Week 24; low; n= 307, 307 | 25 | 39 |
| Week 24; medium; n= 307, 307 | 83 | 76 |
| Week 24; high; n= 307,307 | 199 | 192 |
| Week 48; low; n= 307, 307 | 28 | 52 |
| Week 48; medium; n= 307, 307 | 74 | 82 |
| Week 48; high; n= 307, 307 | 205 | 173 |
Collected over All-cause mortality, Serious adverse events (SAEs) and non-SAEs were collected up to Week 52 for Randomized Phase; up to Week 295 for Continuation Phase and up to Week 348 for Randomized Phase+Continuation Phase.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants Receiving DTG-Randomized Phase | 2/314 (0.6%) | 20/314 (6.4%) | 155/314 (49.4%) |
| Participants Receiving LPV/RTV-Randomized Phase | 3/310 (1%) | 20/310 (6.5%) | 202/310 (65.2%) |
| Participants Receiving DTG-Continuation Phase | 3/274 (1.1%) | 29/274 (10.6%) | 150/274 (54.7%) |
| DTG in Randomized Phase Followed by Continuation Phase | 5/314 (1.6%) | 47/314 (15%) | 218/314 (69.4%) |
| LPV/RTV-Randomized Phase Followed by DTG in Continuation Phase | 3/310 (1%) | 20/310 (6.5%) | 213/310 (68.7%) |
| Event | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase | Participants Receiving DTG-Continuation Phase | DTG in Randomized Phase Followed by Continuation Phase | LPV/RTV-Randomized Phase Followed by DTG in Continuation Phase |
|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 3/314 | 5/310 | 0/274 | 3/314 | 5/310 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/314 | 0/310 | 3/274 | 5/314 | 0/310 |
| Tibia fractureInjury, poisoning and procedural complications | 0/314 | 0/310 | 3/274 | 3/314 | 0/310 |
| AnaemiaBlood and lymphatic system disorders | 2/314 | 2/310 | 1/274 | 3/314 | 2/310 |
| Cerebral toxoplasmosisInfections and infestations | 1/314 | 2/310 | 0/274 | 1/314 | 2/310 |
| Immune reconstitution inflammatory syndromeImmune system disorders | 0/314 | 2/310 | 0/274 | 0/314 | 2/310 |
| Pericardial effusionCardiac disorders | 1/314 | 0/310 | 1/274 | 2/314 | 0/310 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/314 | 0/310 | 1/274 | 2/314 | 0/310 |
| Drug-induced liver injuryHepatobiliary disorders | 1/314 | 0/310 | 1/274 | 2/314 | 0/310 |
| HypokalaemiaMetabolism and nutrition disorders | 1/314 | 0/310 | 1/274 | 2/314 | 0/310 |
| Event | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase | Participants Receiving DTG-Continuation Phase | DTG in Randomized Phase Followed by Continuation Phase | LPV/RTV-Randomized Phase Followed by DTG in Continuation Phase |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 28/314 | 105/310 | 19/274 | 38/314 | 105/310 |
| Upper respiratory tract infectionInfections and infestations | 45/314 | 43/310 | 65/274 | 83/314 | 43/310 |
| HeadacheNervous system disorders | 24/314 | 16/310 | 13/274 | 37/314 | 16/310 |
| NauseaGastrointestinal disorders | 10/314 | 30/310 | 5/274 | 14/314 | 30/310 |
| CoughRespiratory, thoracic and mediastinal disorders | 14/314 | 10/310 | 16/274 | 27/314 | 10/310 |
| Back painMusculoskeletal and connective tissue disorders | 0/314 | 0/310 | 19/274 | 24/314 | 7/310 |
| Lower respiratory tract infectionInfections and infestations | 13/314 | 14/310 | 16/274 | 22/314 | 14/310 |
| VomitingGastrointestinal disorders | 5/314 | 21/310 | 2/274 | 6/314 | 21/310 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/314 | 7/310 | 12/274 | 20/314 | 7/310 |
| DyspepsiaGastrointestinal disorders | 10/314 | 12/310 | 9/274 | 19/314 | 12/310 |
Baseline Characteristic data are reported for members of the ITT-E Population which comprised of all participants who received at least one dose of study medication.
| Age, Continuous(Years) | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase | Total |
|---|---|---|---|
| Mean | 37.5 ± 9.13 | 38.7 ± 9.35 | 38.1 ± 9.25 |
| Sex: Female, Male(Participants) | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase | Total |
|---|---|---|---|
| Female | 116 | 103 | 219 |
| Male | 196 | 209 | 405 |
| Race/Ethnicity, Customized(Participants) | Participants Receiving DTG-Randomized Phase | Participants Receiving LPV/RTV-Randomized Phase | Total |
|---|---|---|---|
| Race, customized — American Indian or Alaska native | 42 | 53 | 95 |
| Race, customized — Asian- Central/South Asian Heritage | 1 | 0 | 1 |
| Race, customized — Asian - East Asian Heritage | 21 | 31 | 52 |
| Race, customized — Asian - South East Asian Heritage | 28 | 25 | 53 |
| Race, customized — White - Arabic/North African Heritage | 2 | 0 | 2 |
| Race, customized — White - White/Caucasian/European Heritage | 88 | 90 | 178 |
| Race, customized — Mixed White Race | 0 | 1 | 1 |
| Race, customized — Black or African American Heritage | 130 | 112 | 242 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · viivhealthcare.com
Ran from Dec 2014 to primary completion in Aug 2017, 31 months.
Results were first posted in Jul 2019, 1 year 11 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 31 months is above that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dolutegravir